CASI Pharma Acquires HBV Treatment for China Use from Indian Pharma

CASI Pharma, a Maryland-Beijing biopharma, acquired a US FDA-approved abbreviated new drug application from Laurus Labs of India, for tenofovir disoproxil fumarate (TDF), a first-line treatment for hepatitis B. CASI will use the ANDA to apply for approval of the generic drug in China. China is home to 90 million people with HBV, one-third of the world's total. CASI will make upfront and milestone payments to Laurus, though details were not disclosed. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:

Original Article: CASI Pharma Acquires HBV Treatment for China Use from Indian Pharma

More From BioPortfolio on "CASI Pharma Acquires HBV Treatment for China Use from Indian Pharma"